Q-omics provides the consensus-scored TRIM39 profile across patient tissues and cancer cell-line models. TRIM39 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TRIM39 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TRIM39 RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, THCA, and ACC as cancer lineages where TRIM39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM39 survival associations across molecular data types. TRIM39 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM39 RNA expression–survival associations across cancer types. High TRIM39 expression shows unfavorable associations in COAD and KICH, but favorable associations in PAAD, BLCA, KIRC and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TRIM39 RNA expression.
This table summarizes TRIM39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM39 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher TRIM39 RNA expression in normal versus tumor tissue (log2 FC = −0.628, t-test p < 0.001).
This table shows molecular features associated with TRIM39 in patient tissues and cancer cell lines. In patient samples, TRIM39 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
